BioSpace News Archive

Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.

PacBio announced financial results for the quarter ended March 31, 2023.

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies and broader biopharma markets, announced the Company’s first quarter financial results will be released after market close on Wednesday, May 10, 2023.

University Cancer & Blood Center will open its Comprehensive Cancer Center in August, offering a fully integrated approach to cancer care with incomparable, convenient access.

Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.

Penumbra, Inc., a global healthcare company focused on innovative therapies, reported financial results for the first quarter ended March 31, 2023.

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported financial results and provided a business update for the quarter ended March 31, 2023.

Hologic, Inc. announced that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced that it will host its first quarter 2023 operating and financial results webcast on Tuesday, May 9, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Astria Therapeutics, Inc. granted stock options to purchase 12,000 shares of Astria’s common stock on May 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.